Eli Lilly and Company

Vertex Pharmaceuticals, Inc.

Cristina Garcia-paredes

Ivan Collado

Mark Joseph Tebbe

Deqi Guo

Ling Jin

John Irvin Glass

Q. May Wang

Xicheng David Sun

Raymond Samuel, Iii Parker

Frantz Victor

Yvonne Yee Mai Yip

Robert Edward Babine

Shu Hui Chen

Jason Eric Lamar

Nancy June Snyder

Q May Wang

Cristina Garcia-Paredes

Raymond Samuel Parker, Iii

Luc J Farmer

Robert B Perni

Guoxin Zhu

Scott Eugene Conner

Mark Donald Chappell

Philip Arthur Hipskind

Michael J Rodriguez

Jolie Anne Bastian

James Robert Henry

Richard Duane Johnston

Almudena Rubio

Gaiying Zhao

David Anthony Barda

Jianke Li

Allie Edward Tripp

Mohammad Sadegh Zia-Ebrahimi

Kelly Wayne Furness

Santiago Carballares Martin

Chong Si

Shu-Hui Chen

Tao Liu

Isabel Cristina Gonzalez Valcarcel

Rebecca Anne Owens

Pablo Garcia Losada

Isabel Rojo

Wenceslao Lumeras Amador

Sonia Maria Gutierrez Sanfeliciano

Julie Sue Moyers

Maria Lourdes Prieto Vallejo

Victoriano Molero Florez

Matthew Patrick Baumgartner

Mario Barberis

Deqi Duo

Samuel Raymond Iii Parker

Raymond Samuel Iii Parker

Samuel Raymond Parker Iii

Mai Yee Yvonne Yip

Iii Parker Raymond Samuel

May Q Wang

The present invention provides compounds of the formula:

KRas inhibitors

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Peptidomimetic protease inhibitors

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Glucagon receptor antagonists, preparation and therapeutic uses

Growing community of inventors

Indianapolis, IN, United States of America

Jason Eric Lamar